| Followers | 2421 |
| Posts | 92347 |
| Boards Moderated | 1 |
| Alias Born | 09/12/2003 |
Friday, June 16, 2023 4:30:11 AM
(Patent # US 9,622,970 B2 ) for Eye Health due to Myopia and Presbyopia is valued at US$570,000,000 by Grant Thornton.” (Patent # us 8,114,444 B2 ) for glucose management. The patent has a valuation of US$210/m as valued by Grant Thornton Accounting Firm.
Grant Thornton Accounting Firm is ranked top 6th worldwide, rankings based on the revenue of USD 7.2 billion.
The International Accounting Bulletin (IAB) has published its 2023 World Survey and we are pleased to share that Grant Thornton is ranked 6th in the global rankings based on revenue and headcount. Globally, we have recorded a revenue of USD 7.2 billion (up by 13.7% from prior year) and a headcount of 68,000 (up by 9.6% from prior year).
FROM THE 10-Q - 08/2022
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class II medical device, the Lung Flute™. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.
The Lung Flute™ is a FDA-cleared Class II medical device that has been cleared by the FDA for both diagnostic and therapeutic use in the U.S. and has received the CE mark clearance for use in the European Union1. It facilitates effective airway clearance by generating and delivering a specific low-frequency sound that vibrates the airways and lung secretions, causing lung secretions to thin and become more mobile2. It is used to help clear respiratory tract secretions in patients with chronic obstructive pulmonary disease (COPD) which results in an improved quality of life1
Recent BDPT News
- BioAdaptives introduces MyndSystem™, an integrated Neuro-Performance & Repair system for day and night • GlobeNewswire Inc. • 04/28/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2026 08:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:45:46 AM
- BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing • GlobeNewswire Inc. • 10/07/2025 03:48:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 07:16:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:05:36 PM

